Share your research articles, interpretations and experiences here. Let us know how these studies affect you and your decisions.
Posted on: Aug 27, 2020 12:12PM
The DESTINY-Breast04 trial is a phase III trial for people diagnosed with metastatic breast cancer with low HER2 levels or other stages of breast cancer with low HER2 levels that can't be removed with surgery. For the purposes of this study, breast cancer with low HER2 levels means the cancer has a score of 2+ or 1+ on an immunohistochemistry (IHC) HER2 test or a negative fluorescence in situ hybridization (FISH) HER2 test. Breast cancer with these IHC or FISH scores would usually be considered HER2-negative breast cancer. Still, earlier studies have shown that the medicine being studied may help treat breast cancers with extremely low HER2 levels, which is why this larger study is being done.
The cancer also must have been previously treated with one or two chemotherapy regimens for people to be eligible for this study.
The trial is looking to see if the medicine fam-trastuzumab-deruxtecan-nxki offers more benefits than your doctor's choice of four chemotherapy medicines: